Indeed, in Rosenzweig et al., it was stated that “...the beneficial effect of the immunotherapy for AD and dementia does not require continuous exposure to the antibody, and that the effect is mechanistically different from that underlying the current anti-PD-L1 treatment used in cancer therapy” (Rosenzweig et al., 2019). Here, CD274 is linked to Alzheimer disease.